161 related articles for article (PubMed ID: 37459096)
1. Concomitant Discontinuation of Cardiovascular Therapy and Adjuvant Hormone Therapy Among Patients With Breast Cancer.
He W; Zeng E; Sjölander A; Hübbert L; Hedayati E; Czene K
JAMA Netw Open; 2023 Jul; 6(7):e2323752. PubMed ID: 37459096
[TBL] [Abstract][Full Text] [Related]
2. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening.
He W; Eriksson L; Törnberg S; Strand F; Hall P; Czene K
BMC Med; 2019 Jan; 17(1):24. PubMed ID: 30700300
[TBL] [Abstract][Full Text] [Related]
4. Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis.
Zeng E; He W; Sjölander A; Bergqvist J; Fang F; Czene K
J Natl Cancer Inst; 2024 Jun; 116(6):920-928. PubMed ID: 38471102
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
He W; Fang F; Varnum C; Eriksson M; Hall P; Czene K
J Clin Oncol; 2015 Jul; 33(20):2262-9. PubMed ID: 26033800
[TBL] [Abstract][Full Text] [Related]
6. Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients.
Mao D; Hachem H; Chang H; Dima D; Dower J; Wismer M; Erban JK; Freund KM; Parsons SK
Breast Cancer Res Treat; 2020 Dec; 184(3):665-674. PubMed ID: 32918658
[TBL] [Abstract][Full Text] [Related]
7. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
He W; Smedby KE; Fang F; Olsson H; Margolin S; Hall P; Czene K
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28423398
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy.
Rea F; Biffi A; Ronco R; Franchi M; Cammarota S; Citarella A; Conti V; Filippelli A; Sellitto C; Corrao G
JAMA Netw Open; 2021 Jun; 4(6):e2113186. PubMed ID: 34125221
[TBL] [Abstract][Full Text] [Related]
9. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
Harborg S; Heide-Jørgensen U; Ahern TP; Ewertz M; Cronin-Fenton D; Borgquist S
Breast Cancer Res Treat; 2020 Aug; 183(1):153-160. PubMed ID: 32572715
[TBL] [Abstract][Full Text] [Related]
10. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
Farias AJ; Du XL
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
[No Abstract] [Full Text] [Related]
11. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
[TBL] [Abstract][Full Text] [Related]
12. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
[TBL] [Abstract][Full Text] [Related]
13. Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).
Bluethmann SM; Alfano CM; Clapp JD; Luta G; Small BJ; Hurria A; Cohen HJ; Sugarman S; B Muss H; Isaacs C; Mandelblatt JS
Breast Cancer Res Treat; 2017 Oct; 165(3):677-686. PubMed ID: 28653250
[TBL] [Abstract][Full Text] [Related]
14. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.
Hershman DL; Shao T; Kushi LH; Buono D; Tsai WY; Fehrenbacher L; Kwan M; Gomez SL; Neugut AI
Breast Cancer Res Treat; 2011 Apr; 126(2):529-37. PubMed ID: 20803066
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Hormone Therapy-Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis.
Zeng E; He W; Smedby KE; Czene K
J Natl Compr Canc Netw; 2022 Apr; 20(6):683-689.e2. PubMed ID: 35385829
[TBL] [Abstract][Full Text] [Related]
16. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
17. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
18. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden.
Johansson A; Christakou AE; Iftimi A; Eriksson M; Tapia J; Skoog L; Benz CC; Rodriguez-Wallberg KA; Hall P; Czene K; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114716. PubMed ID: 34170304
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival.
Wang SY; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP; Chen J
Breast Cancer Res Treat; 2014 Jul; 146(2):411-9. PubMed ID: 24951268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
